CrystalGenomics, a partner biopharmaceutical company of Standigm, finds first evidence to a new AI-driven drug for cancer.


CrystalGenomics, Inc., Standigm’s partner company, today announced a drug predicted by Standigm’s artificial intelligence technology showed the evidence that it may reuse for cancer treatment. The drug is an FDA-proved drug for other therapeutic uses. It has been only three months to sign the partnership between Standigm, Inc. and CrystalGenomics, Inc.

Read more in Korean press

Biospectator, 약업뉴스

Tags: AI-driven drug discovery , Cancer , CrystalGenomics , Experimental validation , Standigm

Categories: News